ClinicalTrials.gg
Not yet recruitingNCT07418814Updated Feb 18, 2026

Infant Massage for Lymphedema and Comfort in Preterm Newborns

An interventional study of Infant Massage Group in Lymphedema, Premature Birth and Edema, sponsored by Erzurum Technical University. Not yet recruiting. Open to participants aged 28 Weeks to 37 Weeks. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Erzurum Technical University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
28 Weeks to 37 Weeks
Sex
All
01

Study summary

This randomized controlled trial investigates the effectiveness of infant massage in reducing symptoms of immobilization-related lymphedema and improving comfort in preterm newborns hospitalized in the Neonatal Intensive Care Unit (NICU). Preterm infants frequently develop lymphedema due to their immature circulatory systems and prolonged lack of movement.

The study compares two groups of infants: one receiving standard care and another receiving a daily 15-minute massage therapy session for 14 consecutive days in addition to standard care. Researchers will evaluate the impact of the massage by measuring the circumference of the infants' wrists, elbows, ankles, and knees to assess fluid reduction. Additionally, the infants' comfort levels will be assessed using the Premature Infant Comfort Scale (PICS). The goal is to determine if massage can serve as a safe, non-invasive method to manage lymphedema and reduce distress in this vulnerable population.

Read the detailed description

Preterm infants born before the 37th week of gestation frequently encounter health challenges due to immature physiological systems, with lymphedema being a significant clinical concern precipitated by circulatory insufficiency and prolonged immobilization in the Neonatal Intensive Care Unit (NICU). This condition is characterized by abnormal fluid accumulation that, if untreated, can lead to chronic pain, infection risks, and developmental delays. While manual lymphatic drainage is the standard for adults, its application in preterm infants is limited due to skin fragility, and surgical options carry substantial risks. Consequently, there is an urgent need for non-invasive approaches to facilitate fluid movement in the absence of natural physical activity.

Although infant massage is known to enhance weight gain and reduce stress, its specific efficacy in mitigating immobilization-related lymphedema through mechanical drainage has not been rigorously examined. This randomized controlled trial aims to evaluate the clinical effectiveness of infant massage as a non-invasive intervention for reducing lymphedema symptoms and enhancing comfort levels among preterm neonates. The study will be conducted at a Level III NICU, involving preterm infants hospitalized for a minimum of two weeks who meet specific eligibility criteria, including hemodynamic stability and a diagnosis of lymphedema.

Participants will be randomized into an intervention group receiving standardized massage therapy and a control group receiving standard care. The intervention consists of a 15-minute daily massage regimen applied for 14 consecutive days, focusing on affected extremities and lymphatic regions using an oil-free, hypoallergenic formula. Primary outcomes, including extremity circumference measurements (wrist, elbow, ankle, knee) and pitting edema grading, will be assessed on Day 0, Day 7, and Day 14. Secondary outcomes involving neonatal comfort will be evaluated using the Premature Infant Comfort Scale (PICS). The study seeks to determine whether mechanical stimulation can effectively mitigate fluid accumulation and alleviate physiological distress in this vulnerable population.

02

Conditions studied

  • Lymphedema
  • Premature Birth
  • Edema
  • Immobilization

Keywords

  • Infant Massage
  • Preterm Infant
  • Lymphedema
  • Neonatal Comfort
  • Massage Therapy
  • Immobilization
03

In context

Lymphedema

529 studies on the registry are indexed under Lymphedema; 131 are open to participants now.

This study's planned enrollment of 40 is below the median of 50 across 369 interventional studies indexed under Lymphedema.

Browse Lymphedema studies →

Lead sponsor

Erzurum Technical University is the lead sponsor of 32 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 37 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To ensure a homogenous and clinically stable sample, infants meeting the following criteria will be recruited:

  • Clinical diagnosis of lymphedema.
  • Hemodynamic and clinical stability.
  • No current or recent (within 24 hours) administration of analgesic or sedative medications that could mask comfort assessments.
  • Intact skin integrity with no for topical massage.
  • Absence of congenital heart disease or neurological disorders (antenatal or postnatal diagnosis).
  • No immediate requirement for endotracheal aspiration.
  • Requirement for only non-invasive respiratory support (e.g., nCPAP).
  • Provision of written by the legal guardians (parents).

Exclusion criteria

Exclusion Criteria:

Infants will be excluded if they present with:

  • Major congenital anomalies.
  • Severe respiratory, cardiac, or neurological instability during the study period.
  • Any acute medical identified by the attending neonatologist.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Infant Massage Group

    The massage application consists of gentle tactile stimulation targeting the extremities and lymphatic drainage pathways. The therapy is performed for 15 minutes once daily for 14 days by a trained researcher/nurse. The technique is adapted for preterm physiology to ensure safety and comfort.

    Behavioral: Infant Massage Group

  • No intervention
    Control Group

    Routine clinical management provided to preterm infants in the NICU, including standard medical treatment, feeding, positioning, and hygiene care according to the unit's protocols.

Interventions

  • BehavioralInfant Massage Group

    The intervention involves a standardized infant massage therapy protocol applied by a trained researcher. The massage consists of gentle tactile stimulation targeting the upper and lower extremities to facilitate lymphatic drainage. The sessions are conducted for 15 minutes, once daily, for a period of 14 consecutive days. This intervention is provided in addition to standard NICU care.

06

What researchers measure

Primary outcomes

  1. Change in Extremity Circumference

    Circumference measurements of the upper and lower extremities (specifically the wrist, elbow, ankle, and knee) will be taken using a non-elastic tape measure. Measurements are recorded in centimeters to assess the reduction of fluid accumulation. A decrease in circumference indicates improvement in lymphedema symptoms.

    Time frame: Baseline (Day 0), Day 7, and Day 14

  2. Change in Pitting Edema Grade

    Pitting edema severity is assessed by applying gentle pressure to the edematous area for 5 seconds and observing the depth and duration of the indentation (pitting). It is graded on a standard clinical scale (e.g., +1 to +4), where higher scores indicate more severe edema and lower scores indicate improvement.

    Time frame: Baseline (Day 0), Day 7, and Day 14

Secondary outcomes

  1. Change in Comfort Level (Premature Infant Comfort Scale)

    Neonatal comfort is assessed using the Premature Infant Comfort Scale. The scale consists of 7 items, each scored from 1 to 5. The total score ranges from 7 to 35. A score of 35 indicates the lowest level of comfort (highest distress), while a score of 7 indicates the highest level of comfort. Higher scores indicate lower comfort levels (worse outcome).

    Time frame: Baseline (Day 0), Day 7, and Day 14 (Assessed before and after the intervention)

  2. Change in Heart Rate

    Heart rate is monitored to evaluate the infant's physiological response to the massage. It is measured in beats per minute (bpm).

    Time frame: Baseline (Day 0), Day 7, and Day 14 (Measured before, during, and after intervention)

  3. Change in Oxygen Saturation

    Oxygen saturation levels are monitored to assess respiratory stability and physiological comfort. It is measured as a percentage (SpO2 %).

    Time frame: Baseline (Day 0), Day 7, and Day 14 (Measured before, during, and after intervention)

  4. Change in Body Temperature

    Body temperature is recorded to monitor thermoregulation during the massage application. It is measured in degrees Celsius (°C).

    Time frame: Baseline (Day 0), Day 7, and Day 14 (Measured before, during, and after intervention)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to privacy laws and ethical restrictions.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07418814
Lead sponsor
Erzurum Technical University
Responsible party
Birgül Tuncay (Assistant Professor, Erzurum Technical University) — Principal investigator
First posted
Feb 18, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Birgül Tuncay, PhD
Contact
birgul.tuncay@erzurum.edu.tr
05337615764
Ayşe Gürol, PhD
study director · Erzurum Technical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion